Prosecution Insights
Last updated: August 14, 2026

Decibel Therapeutics Inc.

7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
5
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Due ≤ 30 days (1)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (57%)
2
Medium (29%)
1
Easy (14%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (29%)
§112 only1 (14%)
Multi-statute (no §101)4 (57%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LARA, CAROLINE MONSERRAT 1 100.0% +0.0%
POPA, ILEANA 1 21.4% +14.6%
KONOPKA, CATHERINE ANNE 1 58.2% +64.5%
SINGH, ANOOP KUMAR 1 42.8% +67.4%
TRAN, CHRISTINA L 1 48.2% +45.5%
VIJAYARAGHAVAN, JAGAMYA NMN 1 60.0% +48.2%
REYNOLDS, FRED H 1 33.1% +39.0%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18626156 MODIFIED REP-CAP PLASMIDS AND USES THEREOF LARA, CAROLINE MONSERRAT
18289028 COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING STEREOCILIN DUAL VECTOR SYSTEMS POPA, ILEANA
18278053 METHODS AND COMPOSITIONS FOR REDUCING NUCLEIC ACID VECTOR-INDUCED TOXICITY IN THE INNER EAR KONOPKA, CATHERINE ANNE
17924578 COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION SINGH, ANOOP KUMAR

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
17413223 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE REYNOLDS, FRED H 28d
17735326 COCHLEAR OUTER HAIR CELL PROMOTERS AND USES THEREOF VIJAYARAGHAVAN, JAGAMYA NMN 34d
17794673 METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS TRAN, CHRISTINA L 62d
18289028 COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING STEREOCILIN DUAL VECTOR SYSTEMS POPA, ILEANA
18278053 METHODS AND COMPOSITIONS FOR REDUCING NUCLEIC ACID VECTOR-INDUCED TOXICITY IN THE INNER EAR KONOPKA, CATHERINE ANNE
17924578 COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION SINGH, ANOOP KUMAR

Top Art Units

Art UnitApps
1633 3
1635 1
1632 1
1637 1
1658 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18626156 MODIFIED REP-CAP PLASMIDS AND USES THEREOF LARA, CAROLINE MONSERRAT 1633 §102§103§112 Non-Final OA Pending Apr 03, 2024
18289028 COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING STEREOCILIN DUAL VECTOR SYSTEMS POPA, ILEANA 1633 §103§112 Non-Final OA Pending Oct 31, 2023
18278053 METHODS AND COMPOSITIONS FOR REDUCING NUCLEIC ACID VECTOR-INDUCED TOXICITY IN THE INNER EAR KONOPKA, CATHERINE ANNE 1635 §102§103§112 Non-Final OA Pending Aug 21, 2023
17924578 COMPOSITIONS AND METHODS FOR PROMOTING HAIR CELL REGENERATION SINGH, ANOOP KUMAR 1632 §102§103§112 Final Rejection Pending Nov 10, 2022
17794673 METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS TRAN, CHRISTINA L 1637 §112 Non-Final OA 62d Pending Jul 22, 2022
17735326 COCHLEAR OUTER HAIR CELL PROMOTERS AND USES THEREOF VIJAYARAGHAVAN, JAGAMYA NMN 1633 §103Other Final Rejection 34d Pending May 03, 2022
17413223 COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE REYNOLDS, FRED H 1658 §103 Non-Final OA 28d Pending Jun 11, 2021

Managing Decibel Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month